Federated Hermes’s Keros Therapeutics KROS Stock Holding History

Federated Hermes’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.49M	Buy	700,427 +11,198	+2%	+$125K	0.01%	768
2026 Q1	$7.61M	Buy	689,229 +34,505	+5%	+$533K	0.01%	715
2025 Q4	$13.3M	Buy	654,724 +140,564	+27%	+$2.47M	0.02%	551
2025 Q3	$8.13M	Sell	514,160 -139,870	-21%	-$2.07M	0.01%	613
2025 Q2	$8.73M	Sell	654,030 -570,109	-47%	-$7.7M	0.02%	601
2025 Q1	$12.5M	Buy	1,224,139 +1,099,519	+882%	+$12.8M	0.03%	507
2024 Q4	$1.97M	Buy	+124,620	New	+$6.48M	﹤0.01%	937
2022 Q3	–	Sell	-74	Closed	-$2K	–	2192
2022 Q2	$2K	Buy	+74	New	+$3.25K	﹤0.01%	1984
2021 Q1	–	Sell	-47,703	Closed	-$3.37M	–	2294
2020 Q4	$3.37M	Buy	+47,703	New	+$3.01M	0.01%	916

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Federated Hermes's KROS Position: Q2 2026 in Review

Federated Hermes increased its Keros Therapeutics (KROS) stake by 1.6% in Q2 2026, buying an estimated $125K and bringing the position to 700,427 shares worth $7.49M. The position accounts for 0.01% of the portfolio, ranked #768.

Federated Hermes first reported a position in KROS in Q4 2020 and has held it in 9 quarters since. The position peaked at $13.3M in Q4 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

Federated Hermes held 700,427 shares of Keros Therapeutics worth $7.49M as of Q2 2026.
Federated Hermes bought 11,198 Keros Therapeutics shares in Q2 2026, an estimated $125K.
Keros Therapeutics made up 0.01% of Federated Hermes's portfolio in Q2 2026, its #768 holding.
Federated Hermes first reported a position in Keros Therapeutics in Q4 2020 and has held it in 9 quarters since.
Federated Hermes's Keros Therapeutics position peaked at $13.3M in Q4 2025.
132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.